Sareum Hldgs Plc - Asset Resilience Ratio

Latest as of June 2019: 0.00%

Sareum Hldgs Plc (SAR) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sareum Hldgs Plc strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

£1.00
≈ $1.34 USD Cash + Short-term Investments

Total Assets

£1.24 Million
≈ $1.67 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2021)

This chart shows how Sareum Hldgs Plc's Asset Resilience Ratio has changed over time. See SAR net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Sareum Hldgs Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Sareum Hldgs Plc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents £0.00 0%
Short-term Investments £1.00 0.0%
Total Liquid Assets £1.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Sareum Hldgs Plc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Sareum Hldgs Plc Industry Peers by Asset Resilience Ratio

Compare Sareum Hldgs Plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Sareum Hldgs Plc (2014–2021)

The table below shows the annual Asset Resilience Ratio data for Sareum Hldgs Plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-06-30 87.24% £2.69 Million
≈ $3.61 Million
£3.08 Million
≈ $4.14 Million
-2.39pp
2020-06-30 89.63% £1.79 Million
≈ $2.41 Million
£2.00 Million
≈ $2.69 Million
+89.63pp
2019-06-30 0.00% £1.00
≈ $1.34
£1.24 Million
≈ $1.67 Million
-75.37pp
2018-06-30 75.37% £1.37 Million
≈ $1.84 Million
£1.82 Million
≈ $2.44 Million
-16.45pp
2017-06-30 91.82% £2.30 Million
≈ $3.08 Million
£2.50 Million
≈ $3.36 Million
+80.63pp
2014-06-30 11.18% £200.00K
≈ $268.58K
£1.79 Million
≈ $2.40 Million
--
pp = percentage points

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$3.99 Billion
£2.97 Billion GBP
Market Cap Rank
#24608 Global
#232 in UK
Share Price
£21.50
Change (1 day)
-2.27%
52-Week Range
£12.00 - £27.50
All Time High
£457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more